Colinz Laboratories Ltd
Established in 1986, Colinz Laboratories is Limited is engaged in the manufacturing of Pharmaceutical Formulations like
Allopathic, Ayurvedic and Nutraceuticals in dosage forms of Tablets, Capsules, Ointments, Injectables, Syrups, etc. The company has certain specialized products for Gynecology, cardiology, gastroenterology etc.
- Market Cap ₹ 20.4 Cr.
- Current Price ₹ 44.6
- High / Low ₹ 61.2 / 23.5
- Stock P/E 52.2
- Book Value ₹ 19.7
- Dividend Yield 0.00 %
- ROCE 6.80 %
- ROE 4.54 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 63.7 days to 35.1 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -2.84% over past five years.
- Company has a low return on equity of 3.18% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5.70 | 6.61 | 7.18 | 7.41 | 7.88 | 8.10 | 8.05 | 7.83 | 7.59 | 7.53 | 6.16 | 6.97 | 6.93 | |
5.24 | 6.10 | 6.64 | 7.07 | 7.42 | 7.65 | 7.64 | 7.48 | 7.24 | 7.22 | 5.82 | 6.38 | 6.36 | |
Operating Profit | 0.46 | 0.51 | 0.54 | 0.34 | 0.46 | 0.45 | 0.41 | 0.35 | 0.35 | 0.31 | 0.34 | 0.59 | 0.57 |
OPM % | 8.07% | 7.72% | 7.52% | 4.59% | 5.84% | 5.56% | 5.09% | 4.47% | 4.61% | 4.12% | 5.52% | 8.46% | 8.23% |
0.03 | 0.03 | 0.08 | 0.13 | 0.10 | 0.10 | 0.09 | 0.10 | 0.12 | 0.13 | 0.19 | 0.17 | 0.19 | |
Interest | 0.16 | 0.19 | 0.20 | 0.08 | 0.12 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.09 | 0.08 | 0.05 |
Depreciation | 0.26 | 0.26 | 0.26 | 0.26 | 0.30 | 0.28 | 0.27 | 0.22 | 0.22 | 0.19 | 0.19 | 0.20 | 0.16 |
Profit before tax | 0.07 | 0.09 | 0.16 | 0.13 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.18 | 0.25 | 0.48 | 0.55 |
Tax % | 0.00% | -22.22% | 50.00% | 46.15% | 35.71% | 40.00% | -27.27% | -53.33% | 26.67% | 27.78% | 16.00% | 29.17% | |
Net Profit | 0.07 | 0.11 | 0.08 | 0.07 | 0.10 | 0.09 | 0.14 | 0.23 | 0.12 | 0.13 | 0.21 | 0.34 | 0.39 |
EPS in Rs | 0.15 | 0.24 | 0.18 | 0.15 | 0.22 | 0.20 | 0.31 | 0.50 | 0.26 | 0.28 | 0.46 | 0.74 | 0.85 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 1% |
5 Years: | -3% |
3 Years: | -3% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 19% |
3 Years: | 42% |
TTM: | 44% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 18% |
3 Years: | 64% |
1 Year: | 39% |
Return on Equity | |
---|---|
10 Years: | 2% |
5 Years: | 3% |
3 Years: | 3% |
Last Year: | 5% |
Balance Sheet
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.55 | 3.55 | 2.52 | |
Reserves | 2.48 | 2.64 | 2.71 | 2.78 | 2.62 | 2.71 | 2.98 | 3.21 | 3.30 | 3.29 | 3.75 | 4.14 | 5.44 |
2.85 | 2.39 | 2.26 | 1.88 | 2.53 | 1.80 | 0.76 | 0.42 | 0.68 | 0.38 | 0.99 | 0.48 | 0.57 | |
1.32 | 1.64 | 1.35 | 1.79 | 1.97 | 1.70 | 2.40 | 2.42 | 1.65 | 1.60 | 1.81 | 1.76 | 2.14 | |
Total Liabilities | 10.19 | 10.21 | 9.86 | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.67 |
4.41 | 4.24 | 3.98 | 3.72 | 3.16 | 2.88 | 2.63 | 2.41 | 2.21 | 2.06 | 2.03 | 1.86 | 1.77 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.32 | 0.32 | 0.32 | 0.32 | 0.29 | 0.29 | 0.41 | 0.53 | 0.50 | 0.36 | 0.61 | 0.67 | 0.71 |
5.46 | 5.65 | 5.56 | 5.95 | 7.21 | 6.58 | 6.64 | 6.65 | 6.46 | 6.39 | 7.46 | 7.40 | 8.19 | |
Total Assets | 10.19 | 10.21 | 9.86 | 9.99 | 10.66 | 9.75 | 9.68 | 9.59 | 9.17 | 8.81 | 10.10 | 9.93 | 10.67 |
Cash Flows
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.79 | 0.30 | 0.15 | 0.64 | 0.09 | 0.58 | 0.06 | 0.34 | 0.12 | 0.58 | 2.16 | 0.47 | |
-0.01 | -0.09 | 0.00 | 0.00 | 0.03 | 0.00 | -0.01 | -0.11 | -0.01 | -0.04 | -0.16 | -0.03 | |
-0.26 | -0.45 | -0.14 | -0.37 | 0.45 | -0.73 | -0.03 | 0.01 | 0.02 | 0.06 | 0.08 | 0.09 | |
Net Cash Flow | 0.52 | -0.24 | 0.01 | 0.27 | 0.57 | -0.16 | 0.02 | 0.24 | 0.12 | 0.60 | 2.07 | 0.52 |
Ratios
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 58.91 | 59.64 | 64.56 | 65.51 | 62.53 | 60.83 | 66.65 | 78.31 | 80.79 | 72.22 | 77.03 | 63.36 |
Inventory Days | 318.33 | 290.09 | 237.38 | 188.53 | 288.96 | 232.18 | 267.25 | 266.31 | 246.80 | 225.13 | 208.33 | 147.59 |
Days Payable | 110.00 | 125.30 | 51.05 | 93.17 | 116.24 | 60.66 | 55.68 | 91.93 | 44.16 | 49.29 | 90.00 | 76.17 |
Cash Conversion Cycle | 267.25 | 224.43 | 250.89 | 160.87 | 235.25 | 232.35 | 278.23 | 252.70 | 283.42 | 248.06 | 195.36 | 134.78 |
Working Capital Days | 123.59 | 108.78 | 113.87 | 89.65 | 110.24 | 100.04 | 105.65 | 92.30 | 122.15 | 97.43 | 58.66 | 35.09 |
ROCE % | 2.46% | 3.33% | 4.22% | 2.51% | 3.20% | 3.23% | 3.00% | 3.18% | 3.40% | 3.39% | 4.39% | 6.80% |
Documents
Announcements
- Board Meeting Intimation for Notice Of Date Of Board Meeting Pursuant To Regulation 29(2) Of SEBI (LODR) Regulations, 2015 12 Jan
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Jan - Certificate received from our Registrar and Share Transfer Agent M/s. Bigshare Services Pvt. Ltd. in compliance under Regulation 74(5) of SEBI [Depositories and Participants) Regulations,2018 …
- Closure of Trading Window 30 Dec
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Dec 2022
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Nov 2022 - Newspaper clippings of Un-Audited Financial Results for the quarter and half year ended on 30th September, 2022 published in FREE PRESS JOURNAL and NAVSHAKTI on …
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Product Portfolio:[1]
The company is manufacturing and developing a number of products for various therapeutic segments like:
a) Allopathy:[2]
The company manufactures various Oncology products like Imatinib, Erlotinib, Letrozole, etc. Anti-retroviral like Lopinavir, Indinavir, Ritonavir, etc. and also products belonging to therapeutic segments like Antibiotic; Anti pyretic Anti- Fungal, Anti-malarial, Anti-viral, etc.
b) Ayurvedics:[3]
The company manufactures many Ayurvedic products like Anti-diarrhoeals, Anti-pyretics, Anti-inflammatories, Anti-spasmodics, Cough Syrups, Apetite Stimulating Agents, Memory Boosters, Anti-piles, Antacids, Liver Tonic, etc.
c) Nutraceuticals:[4]
Major products manufactured in the Nutraceutical category are Spirulina Tabs /caps, Spirulina With Vitamins & Minerals, Omega 3 Fatty Acids Caps in Soft gel, Cod-liver Oil With Vitamin Caps in Soft Gel, Collagen, Glucosamine & Chondroitin Tabs, Amino acids tabs/caps, etc.